Technology Is Reshaping Sleep Apnea Treatment

0
93

Inspire therapy—a hypoglossal nerve stimulation implant—has been FDA-approved for more than 11 years, with over 100,000 patients treated across the US, Europe, and Asia. Ruchir Patel, Inspire’s senior medical director, says data show reductions in daytime sleepiness, a 79 percent drop in sleep apnea severity, and a 90 percent reduction in snoring. Early US data report average nightly usage of more than 6.5 hours. “This is an exciting time because there are more treatment options available than in the past,” he says.

Pharmaceutical approaches are also emerging. In 2024, the US Food and Drug Administration approved Zepbound (tirzepatide) for moderate to severe OSA in adults with obesity—the first weight-loss drug to carry a specific sleep apnea indication.

Meanwhile, Cambridge, Massachusetts–based startup Apnimed has developed a nightly pill targeting neuromuscular pathways…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here